Analysis E-cad and VEGF Expression in Triple-negative Breast Cancer of Han and Uygur
-
摘要:目的
分析汉族及维吾尔族女性三阴性乳腺癌（TNBC）患者组织中E-钙黏蛋白（E-cadherin, E-cad）、血管内皮生长因子（vascular endothelial growth factor, VEGF）的表达情况，了解其与预后间的关系。
方法选择新疆医科大学附属肿瘤医院2008年3月—2010年3月汉族TNBC患者140例，维吾尔族57例，检测E-cad、VEGF的表达情况，并与淋巴结转移及TNM分期、组织学分级进行比较，同时观察两组5年无瘤生存率。
结果两组TNBC患者5年无瘤生存率差异无统计学意义（P > 0.05）；E-cad的表达无差别，VEGF阳性率汉族低于维吾尔族（P < 0.05），同时，两组E-cad的表达与淋巴结转移、TNM分期及组织学分级呈负相关（-1≤r < 1, P < 0.05），而VEGF的表达与淋巴结转移及TNM分期呈正相关（0 < r < 1，P < 0.05），但与组织学分级没有明显关系。
结论E-cad在汉族与维吾尔族TNBC中没有表达差异，VEGF阳性率在汉族女性TNBC中低于维吾尔族，但两组5年无瘤生存率没有明显差别，提示维吾尔族TNBC患者可能存在与汉族患者不同的影响其预后的因素，需采取进一步研究证实。
Abstract:ObjectiveTo probe into the expression of E-cadherin(E-cad) and vascular endothelial growth factor (VEGF) in triple negative breast cancer(TNBC) patients of Han and Uygur, and their relationship with the prognosis.
MethodsFrom March 2008 to March 2010, 140 cases of Han and 57 cases of Uygur TNBC patients were admitted. We determined the expression of E-cad and VEGF, compared them with lymph node metastasis, TNM staging and histological grade, and observed the 5-year disease-free survival(DFS).
Results5-year DFS of two groups were not different (P > 0.05). E-cad expression of two groups were not different, and Han patients' VEGF positive rate was lower than Uygur patients (P < 0.05). E-cad expression were negatively associated with lymph node metastasis, TNM stage and histological grade (-1≤r < 1, P < 0.05), while VEGF expression were positively associated with lymph node metastasis and TNM stage (0 < r < 1, P < 0.05), but no significant relationship with histological grade.
ConclusionE-cad expression in the Han and Uygur TNBC patients were not different. The VEGF expression rate of TNBC in the Han group is lower than that in the Uygur group, but no significant difference in the 5-year DFS between two groups, considering Uygur TNBC patients may have different prognostic factors, which needs to take further study.
-
Key words:
- Han /
- Uygur /
- Triple-negative breast cancer /
- E-cad /
- VEGF
-
-
![]()
图 1 E-cad和VEGF免疫组织化学结果(PV-9000, DAB×200)
Figure 1 E-cad and VEGF immunohistochemical expression results (PV-9000, DAB×200)
表 2 E-cad和VEGF在汉族与维吾尔族TNBC患者组织中的表达情况[n(%)]
Table 2 The compare of E-cad and VEGF in Han and Uygur TNBC [n(%)]
下载: 导出CSV
表 3 E-cad和VEGF在汉族与维吾尔族TNBC患者淋巴结分组中的表达情况
Table 3 The compare of E-cad and VEGF with Lymph node in Han and Uygur TNBC
下载: 导出CSV
表 4 E-cad和VEGF在汉族与维吾尔族TNBC患者TNM分期中的表达情况
Table 4 The compare of E-cad and VEGF with TNM in Han and Uygur TNBC
下载: 导出CSV
表 5 E-cad和VEGF在汉族与维吾尔族TNBC患者组织学分级中的表达情况
Table 5 The compare of E-cad and VEGF with grade in Han and Uygur TNBC
下载: 导出CSV
-
[1] Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer[J]. Breast Cancer Res Treat, 2008, 109(1): 123-39. doi: 10.1007/s10549-007-9632-6
[1] Millikan RC, Newman B, Tse CK, et al. Epidemiology of basallike breast cancer[J]. Breast Cancer Res Treat, 2008, 109(1): 12 3-39. [2] Bulut N, Altundag K. Excellent clinical outcome of triple-negative breast cancer in younger and older women[J]. J BUON, 2015, 20 (5): 1276-81. [2] Bulut N, Altundag K. Excellent clinical outcome of triple-negative breast cancer in younger and older women[J]. J BUON, 2015, 20(5): 1276-81. http://paper.medlive.cn/literature/1827800
[3] Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer[J]. Nat Rev Cancer, 2012, 12(1): 23-38. https://www.ncbi.nlm.nih.gov/pubmed/22169974
[3] Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer[J]. Nat Rev Cancer, 2012, 12(1): 23-38. [4] Kim MS, Park TI, Lee YM, et al. Expression of id-1 and VEGF in non-small cell lung cancer[J]. Int J Clin Exp Pathol, 2013, 6(10): 2102-11. http://paper.medlive.cn/literature/2092676
[4] Kim MS, Park TI, Lee YM, et al. Expression of id-1 and VEGF in non-small cell lung cancer[J]. Int J Clin Exp Pathol, 2013, 6(10): 21 02-11. [5] 邱秀娟, 成芳, 刘莹.新疆1006例维吾尔族与汉族不同分子分型乳腺癌患者的临床病理特征及生存分析[J].肿瘤, 2015, 35(3): 292-300. http://www.cnki.com.cn/Article/CJFDTOTAL-ZZLL201503009.htm Qiu XJ, Cheng F, Liu Y. Clinicopathological characteristics and prognosis of 1006 Uygur and Han patients with different molecular subtypes of breast cancer[J]. Zhong Liu, 2015, 35(3): 292-300. http://www.cnki.com.cn/Article/CJFDTOTAL-ZZLL201503009.htm
[5] 邱秀娟, 成芳, 刘莹. 新疆1006例维吾尔族与汉族不同分子分 型乳腺癌患者的临床病理特征及生存分析[J]. 肿瘤, 2015, 35 (3): 292-300. [Qiu XJ, Cheng F, Liu Y. Clinicopathological characteristics and prognosis of 1006 Uygur and Han patients with different molecular subtypes of breast cancer[J]. Zhong Liu, 20 15, 35(3): 292-300.] [6] 蒋威华, 欧江华, 张国庆, 等. 汉族与维吾尔族三阴性乳腺癌临床 特征及预后差异分析[J]. 中国肿瘤临床, 2011, 38(24): 1579-83. [Jiang WH, Ou JH, Zhang GQ, et al. Triple negative breast cancer of Han and Uygur: clinical features and Prognosis[J].Zhongguo Zhong Liu Lin Chuang, 2011, 38(24): 1579-83.] [6] 蒋威华, 欧江华, 张国庆, 等.汉族与维吾尔族三阴性乳腺癌临床特征及预后差异分析[J].中国肿瘤临床, 2011, 38(24): 1579-83. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201124035.htm Jiang WH, Ou JH, Zhang GQ, et al. Triple negative breast cancer of Han and Uygur: clinical features and Prognosis[J].Zhongguo Zhong Liu Lin Chuang, 2011, 38(24): 1579-83. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201124035.htm
[7] Karn T, Rody A, Müller V, et al. Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer[J]. Genom Data, 2014, 2: 354-6. [7] Karn T, Rody A, Müller V, et al. Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer[J]. Genom Data, 2014, 2: 354-6. doi: 10.1016/j.gdata.2014.09.014
[8] Nelson WJ. Regulation of cell-cell adhesion by the cadherin-catenin complex[J]. Biochem Soc Trans, 2008, 36(Pt 2): 149-55. https://www.researchgate.net/publication/5488011_Regulation_of_cell-cell_adhesion_by_the_cadherin-catenin_complex
[8] Nelson WJ. Regulation of cell-cell adhesion by the cadherin-catenin complex[J]. Biochem Soc Trans, 2008, 36(Pt 2): 149-55. [9] Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition[J]. Mol Cancer, 2010, 9: 179. doi: 10.1186/1476-4598-9-179
[9] Chao YL, Shepard CR, Wells A. Breast carcinoma cells reexpress E-cadherin during mesenchymal to epithelial reverting transition[J]. Mol Cancer, 2010, 9: 179. [10] Kashiwagi S, Yashiro M, Takashima T, et al. Significance of E-cadherin expression in triple-negative breast cancer[J].Br J Cancer, 2010, 103(2): 249-55. [10] Kashiwagi S, Yashiro M, Takashima T, et al. Significance of E-cadherin expression in triple-negative breast cancer[J].Br J Cancer, 2010, 103(2): 249-55. doi: 10.1038/sj.bjc.6605735
[11] Tang D, Xu S, Zhang Q, et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer[J]. Med Oncol, 2012, 29(2): 526-33. doi: 10.1007/s12032-011-9948-2
[11] Tang D, Xu S, Zhang Q, et al. The expression and clinical significance of the androgen receptor and E-cadherin in triplenegative breast cancer[J]. Med Oncol, 2012, 29(2): 526-33. [12] Kashiwagi S, Yashiro M, Takashima T, et al. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at StageⅡ: usefulness of prognostic markers E-cadherin and Ki67[J]. Breast Cancer, 2011, 13(6): R122. [12] Kashiwagi S, Yashiro M, Takashima T, et al. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at StageⅡ: usefulness of prognostic markers E-cadherin and Ki67[J]. Breast Cancer, 2011, 13(6): R122. doi: 10.1186/bcr3068
[13] Kim MS, Park TI, Lee YM, et al.Expression of id-1 and VEGF in non-small cell lung cancer[J]. Int J Clin expe Pathol, 2013, 6(10): 2102-11. http://paper.medlive.cn/literature/2092676
[13] Kim MS, Park TI, Lee YM, et al．Expression of id-1 and VEGF in non-small cell lung cancer[J]. Int J Clin expe Pathol, 2013, 6( 10): 2102-11. [14] Greenberg S, Rugo HS. Triple-negative breast cancer:role of antiangiogenic agents[J]. Cancer J (Sdbury Mass), 2010, 16(1): 33-8. doi: 10.1097/PPO.0b013e3181d38514
[14] Greenberg S, Rugo HS. Triple-negative breast cancer：role of antiangiogenic agents[J]. Cancer J (Sdbury Mass), 2010, 16(1): 33-8. [15] Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascula r endothelial growth factor(VEGF) and shorter survival times for patients with primary operable triplenegative breast cancer[J]. Ann Oncol, 2009, 20(10): 1639-46. [15] Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascula r endothelial growth factor(VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer[J]. Ann Oncol, 2009, 20(10): 1639-46. doi: 10.1093/annonc/mdp062
[16] Bahhnassy A, Mohanad M, Shaarawy S, et al. Transforming growth factor-β, insulin-like growth factorⅠ/insulin-like growth factorⅠ receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer[J]. Mol Med Rep, 2015, 12(1): 851-64. [16] Bahhnassy A, Mohanad M, Shaarawy S, et al. Transforming growth factor-β, insulin-like growth factorⅠ/insulin-like growth factorⅠreceptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer[J]. Mol Med Rep, 2015, 12(1): 851-64. https://www.spandidos-publications.com/mmr/12/1/851
[17] Minkwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer[J]. N Engl J Med, 2012, 366(4): 299-309. [17] Minkwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer[J]. N Engl J Med, 2012, 366(4): 299-309. doi: 10.1056/NEJMoa1111065
[18] Canel M, Serrels A, Frame MC, et al. E-cadherin-integrin crosstalk in cancer invasion and metastasis[J]. J Cell Sci, 2013, 126(Pt 2): 393-401. https://www.ncbi.nlm.nih.gov/pubmed/23525005
[18] Canel M, Serrels A, Frame MC, et al. E-cadherin-integrin crosstalk in cancer invasion and metastasis[J]. J Cell Sci, 2013, 126(Pt 2): 39 3-401. [19] Techasen A, Loilome W, Namwat N, et al. Loss of E-cadherin promotes migration and invasion of cholangiocarcinoma cells and serves as a potential marker of metastasis[J]. Tumour Biol, 2014, 35 (9): 8645-52． [19] Techasen A, Loilome W, Namwat N, et al. Loss of E-cadherin promotes migration and invasion of cholangiocarcinoma cells and serves as a potential marker of metastasis[J]. Tumour Biol, 2014, 35(9): 8645-52. doi: 10.1007/s13277-014-2087-6
[20] Pang H, Lu H, Song H, et al. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer[J]. Cancer Epidemiol, 2013, 37(6): 985-92. doi: 10.1016/j.canep.2013.08.005
[20] Pang H, Lu H, Song H, et al. Prognostic values of osteopontinc, E-cadherin and β-catenin in breast cancer[J]. Cancer Epidemiol, 20 13, 37(6): 985-92． [21] 孙弢, 姚宇锋, 龚建平, 等. E-钙黏蛋白在三阴性乳腺癌组织中的表达[J].肿瘤基础与临床, 2014, 27(1): 8-10. http://mall.cnki.net/magazine/article/hlzl201401004.htm Sun T, Yao YF, Gong JP, et al. Expression of E-cadherin in the Triple Negative Breast Cancer[J]. Zhong Liu Ji Chu Yu Lin Chuang, 2014, 27(1): 8-10. http://mall.cnki.net/magazine/article/hlzl201401004.htm
[21] 孙弢, 姚宇锋, 龚建平, 等. E-钙黏蛋白在三阴性乳腺癌组织中 的表达[J]. 肿瘤基础与临床, 2014, 27(1): 8-10. [Sun T, Yao YF, Gong JP, et al. Expression of E-cadherin in the Triple Negative Breast Cancer[J]. Zhong Liu Ji Chu Yu Lin Chuang, 2014, 27(1): 8- 10.] [22] Rakha EA, EI-sayed ME, Green AR, et al. prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109(1): 25-32． [22] Rakha EA, EI-sayed ME, Green AR, et al. prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109(1): 25-32. doi: 10.1002/(ISSN)1097-0142
[23] Tsai CH, Chiu JH, Yang CW, et al. Molecular characteristics of recurrent triple-negative breast cancer[J]. Mol Med Rep, 2015, 12(5): 7326-34. https://www.researchgate.net/publication/282876811_Molecular_characteristics_of_recurrent_triple-negative_breast_cancer
[23] Tsai CH, Chiu JH, Yang CW, et al. Molecular characteristics of recurrent triple-negative breast cancer[J]. Mol Med Rep, 2015, 12 (5): 7326-34. [24] Jobim FC, SchwartsmannG, Xavier NL, et al. Expression of MMP-9 and VEGF in breast cancer :correlation with other prognostic indicators[J]．Rev Bras Ginecol Obstct，2008, 30(6): 28 7-93． [24] Jobim FC, SchwartsmannG, Xavier NL, et al. Expression of MMP-9 and VEGF in breast cancer :correlation with other prognostic indicators[J].Rev Bras Ginecol Obstct, 2008, 30(6): 287-93. doi: 10.1590/S0100-72032008000600004
[25] Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets[J]. Proc Natl Acad Sci U S A , 2003, 100(14): 8418-23． [25] Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets[J].Proc Natl Acad Sci U S A, 2003, 100(14): 8418-23. doi: 10.1073/pnas.0932692100
计量
- 文章访问数: 1442
- HTML全文浏览量: 318
- PDF下载量: 332
